Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | GABRP | O00591 | 4/20 | 0.43 |
| ▸ | GABRD | O14764 | 4/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.43 |
| ▸ | GABRA4 | P48169 | 4/20 | 0.43 |
| ▸ | GABRE | P78334 | 4/20 | 0.43 |
| ▸ | GABRA6 | Q16445 | 4/20 | 0.43 |
| ▸ | GABRG1 | Q8N1C3 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2842356 | 0.88 | KEAP1 (0.40) | POLBLMNAMAPTTDP1SMN1; SMN2 | |
| SCHEMBL2841927 | 0.87 | MEN1 (0.47) | MAPTNHERF1MEN1KMT2AKEAP1 | |
| SCHEMBL1322546 | 0.84 | GAA (0.43) | LMNAMAPTGAAMEN1KMT2A | |
| SCHEMBL2845985 | 0.83 | POLB (0.51) | POLBLMNAMAPTTDP1GAA | |
| SCHEMBL2846006 | 0.83 | PLAU (0.41) | SMN1; SMN2KEAP1NFE2L2 | |
| SCHEMBL2848207 | 0.81 | KEAP1 (0.41) | SMN1; SMN2KEAP1NFE2L2 | |
| SCHEMBL2850634 | 0.80 | TP53 (0.39) | MEN1KMT2AKEAP1NFE2L2 | |
| SCHEMBL12116672 | 0.79 | NR1H4 (0.47) | POLBLMNANAMPTNPC1RAB9A | |
| SCHEMBL1321018 | 0.79 | KEAP1 (0.58) | KEAP1NFE2L2 | |
| SCHEMBL1319769 | 0.79 | GAA (0.42) | GAAMEN1KMT2AKDM4EKEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232312-B2 | Substituted arylsulphonylglycines, the preparation thereof and the use thereof as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-31 | — | — | US | disclosed |
| US-8232312-B2 | Substituted arylsulphonylglycines, the preparation thereof and the use thereof as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-31 | — | — | US | disclosed |
| US-8232312-B2 | Substituted arylsulphonylglycines, the preparation thereof and the use thereof as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-31 | — | — | US | disclosed |
| EP-2125718-B1 | NEW SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2010-09-15 | — | — | EP | disclosed |
| US-20100130557-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-27 | — | — | US | disclosed |
| US-20100130557-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-27 | — | — | US | disclosed |
| US-20100130557-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-27 | — | — | US | disclosed |
| EP-2125718-A2 | NEW SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | Boehringer Ingelheim International GmbH (DE) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008113760-A2 | ARYLSULPHONYGLYCINE DERIVATIVES AS SUPPRESSORS OF THE INTERACTION OF GLYCOGEN PHOSPHORYLASE A WITH THE GL SUBUNIT OF GLYCOGEN-ASSOCIATED PROTEIN PHOSPHATASE 1 (PPL) FOR THE TREATMENT OF METABOLIC DISORDERS, PARTICULARY DIABETES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008113760-A2 | ARYLSULPHONYGLYCINE DERIVATIVES AS SUPPRESSORS OF THE INTERACTION OF GLYCOGEN PHOSPHORYLASE A WITH THE GL SUBUNIT OF GLYCOGEN-ASSOCIATED PROTEIN PHOSPHATASE 1 (PPL) FOR THE TREATMENT OF METABOLIC DISORDERS, PARTICULARY DIABETES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130557-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | PYGL, PYGM, G6PC1 | POLB 3950/4885LMNA 1193/4885MAPT 911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.